Cargando…
Response to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial”
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071439/ https://www.ncbi.nlm.nih.gov/pubmed/30123789 http://dx.doi.org/10.4103/abr.abr_81_18 |
| _version_ | 1783343870867668992 |
|---|---|
| author | Patil, Anant D |
| author_facet | Patil, Anant D |
| author_sort | Patil, Anant D |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6071439 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Medknow Publications & Media Pvt Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-60714392018-08-17 Response to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial” Patil, Anant D Adv Biomed Res Letter to Editor Medknow Publications & Media Pvt Ltd 2018-07-20 /pmc/articles/PMC6071439/ /pubmed/30123789 http://dx.doi.org/10.4103/abr.abr_81_18 Text en Copyright: © 2018 Advanced Biomedical Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
| spellingShingle | Letter to Editor Patil, Anant D Response to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial” |
| title | Response to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial” |
| title_full | Response to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial” |
| title_fullStr | Response to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial” |
| title_full_unstemmed | Response to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial” |
| title_short | Response to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial” |
| title_sort | response to “levofloxacin-containing versus clarithromycin-containing therapy for helicobacter pylori eradication: a prospective randomized controlled clinical trial” |
| topic | Letter to Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071439/ https://www.ncbi.nlm.nih.gov/pubmed/30123789 http://dx.doi.org/10.4103/abr.abr_81_18 |
| work_keys_str_mv | AT patilanantd responsetolevofloxacincontainingversusclarithromycincontainingtherapyforhelicobacterpylorieradicationaprospectiverandomizedcontrolledclinicaltrial |